2. Search Result
Search Result
No matches for "

55726

" within the MedChemExpress (MCE) catalog. Here are the results you might be looking for.

17

Inhibitors & Agonists

1

Peptides

1

Recombinant Proteins

5

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117288
    S55746
    1 Publications Verification

    BCL201

    		 Bcl-2 Family Cancer
    S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity .
    S55746
  • HY-104037
    Cintirorgon
    Maximum Cited Publications
    8 Publications Verification

    LYC-55716

    		 ROR Cancer
    Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival .
    Cintirorgon
  • HY-143584
    AZ5576

    		CDK Apoptosis Cancer
    AZ5576 is a potent and highly selective CDK9 inhibitor (IC50: <5 nM). AZ5576 inhibits the phosphorylation of RNA polymerase II at Ser2, thereby inhibiting transcriptional elongation. AZ5576 can be used for hematological Malignancy research .
    AZ5576
  • HY-117288A
    S55746 hydrochloride
    1 Publications Verification

    BCL201 hydrochloride

    		 Bcl-2 Family Cancer
    S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity .
    S55746 hydrochloride
  • HY-105018
    Epelsiban

    GSK 557296

    		 Oxytocin Receptor Endocrinology
    Epelsiban (GSK 557296) is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pKi of 9.9 for human oxytocin receptor.
    Epelsiban
  • HY-19125
    BN-50726

    		Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease Inflammation/Immunology
    BN-50726 is a potent platelet-activating factor (PAF) receptor antagonist. BN-50726 inhibits PAF-induced effects (e.g., [3H]-serotonin release and hypotension) (IC50=5.40 nM). BN-50726 is promising for research of PAF-mediated pathological processes (e.g., inflammation, anaphylaxis, hypotension) .
    BN-50726
  • HY-100151
    RGH-5526

    GYKI-11679

    		 Others Cardiovascular Disease
    RGH-5526 (GYKI-11679) is a new antihypertensive agent.
    RGH-5526
  • HY-P3692
    CART (55-76), rat

    		Neuropeptide Y Receptor Neurological Disease
    CART (55-76), rat is a neuropeptide (55-76 residues of the CART peptide) and constitutes the N-terminal fragments of CART (55-102). CART (55-76), rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (55-76), rat can induce anxiety and stress-related behavior .
    CART (55-76), rat
  • HY-105018A
    Epelsiban besylate

    GSK 557296 benzenesulfonate

    		 Oxytocin Receptor Others
    Epelsiban Besylate (GSK 557296 benzenesulfonate) is an orally active compound known for its highly selective oxytocin receptor antagonist.
    Epelsiban besylate
  • HY-104037A
    Cintirorgon sodium

    LYC-55716 sodium

    		 ROR Cancer
    Cintirorgon sodium is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon sodium (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival .
    Cintirorgon sodium
  • HY-44484
    MAC-5576

    		SARS-CoV Infection
    MAC-5576 is a SARS-CoV-2 3CL protease inhibitor, with an IC50 of 81 nM. MAC-5576 also inhibits 3CLpro (IC50=0.5 μM), HAV 3Cpro (IC50=0.5 μM), and thrombin (IC50=13 μM) .
    MAC-5576
  • HY-111537
    rel-AZ5576

    		c-Myc CDK Bcl-2 Family Others
    rel-AZ5576 is a selective CDK9 inhibitor with the activity of downregulating Mcl-1 and MYC mRNA transcription and protein expression in diffuse large B-cell lymphoma by inhibiting CDK9, promoting MYC protein turnover, reducing MYC phosphorylation on the stable Ser62 residue and downregulating MYC transcriptional targets, inhibiting the growth of diffuse large B-cell lymphoma cell lines in vitro and in vivo and independent of the cell origin.
    rel-AZ5576
  • HY-RI01723A
    hsa-miR-5572 antagomir

    		MicroRNA Cancer
    hsa-miR-5572 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-5572 antagomir
    hsa-miR-5572 antagomir
  • HY-R01723
    hsa-miR-5572 mimic

    		MicroRNA Cancer
    hsa-miR-5572 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-5572 mimic
    hsa-miR-5572 mimic
  • HY-104037R
    Cintirorgon (Standard)

    LYC-55716 (Standard)

    		 Reference Standards ROR Cancer
    Cintirorgon (Standard) is the analytical standard of Cintirorgon (HY-104037). This product is intended for research and analytical applications. Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival .
    Cintirorgon (Standard)
  • HY-R01723A
    hsa-miR-5572 agomir

    		MicroRNA Cancer
    hsa-miR-5572 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-5572 agomir
    hsa-miR-5572 agomir
  • HY-RI01723
    hsa-miR-5572 inhibitor

    		MicroRNA Cancer
    hsa-miR-5572 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-5572 inhibitor
    hsa-miR-5572 inhibitor

Inquiry Online

Submit your filled information, we will contact you soon.

Salutation: * Country or Region:
* Applicant Name: * Organization Name:
* Department:    
* Email Address: * Product Name:
Cat. No.: * Requested quantity:
* Phone Number:    
Remarks:

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: